person · Reporting owner

WHITCOMB RANDALL W

Disclosed activity across 1 company

Tapewire entity: 156541
SEC CIK: 0001218867

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Tempest Therapeutics, Inc.MLND · Entity 7734	Director	June 20, 2019	June 21, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Tempest Therapeutics, Inc.

Report date June 20, 2019 · Filed June 21, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.59 · Expires 2029-06-19	Direct	12,000	Reported balance After 2019-06-20 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-06-20 · Grant · Acquired 12,000 · Balance 12,000 F1: One hundred percent (100%) of the shares subject to this option will vest on June 20, 2020, subject to the Reporting Person continuing to provide service through such date.

Filing footnotes · ownership attribution and instrument terms

F1: One hundred percent (100%) of the shares subject to this option will vest on June 20, 2020, subject to the Reporting Person continuing to provide service through such date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 20, 2019 Filed Jun 21, 2019 16:41 UTC	Tempest Therapeutics, Inc. MLND · Entity 7734	GrantStock Option (right to buy) · Derivative	12,000	$0.00 Strike: $11.59	$0.00	Disclosure SEC source: 0001209191-19-038489 · doc4.xml · derivative · entry 1 WHITCOMB RANDALL W · CIK 0001218867 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2029-06-19 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option will vest on June 20, 2020, subject to the Reporting Person continuing to provide service through such date. Read SEC document
January 15, 2019 Filed Jan 17, 2019 16:52 UTC	Tempest Therapeutics, Inc. MLND · Entity 7734	GrantStock Option (right to buy) · Derivative	6,000	$0.00 Strike: $8.80	$0.00	Disclosure SEC source: 0001209191-19-004246 · doc4.xml · derivative · entry 1 WHITCOMB RANDALL W · CIK 0001218867 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2029-01-14 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option will vest on January 15, 2020, subject to the Reporting Person continuing to provide service through such date. Read SEC document
December 07, 2018 Filed Dec 11, 2018 19:49 UTC	Tempest Therapeutics, Inc. MLND · Entity 7734	GrantStock Option (right to buy) · Derivative	3,720	Not disclosed Strike: $16.40	Not disclosed	Disclosure SEC source: 0001209191-18-062127 · doc4.xml · derivative · entry 3 WHITCOMB RANDALL W · CIK 0001218867 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,720 Underlying: Common Stock · 3,720 shares Expires 2028-08-23 F5 · price: Received in connection with the Merger in exchange for a stock option to acquire 50,000 shares of Millendo common stock for $1.22 per share. F4 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on August 20, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document
December 07, 2018 Filed Dec 11, 2018 19:49 UTC	Tempest Therapeutics, Inc. MLND · Entity 7734	GrantStock Option (right to buy) · Derivative	21,438	Not disclosed Strike: $4.44	Not disclosed	Disclosure SEC source: 0001209191-18-062127 · doc4.xml · derivative · entry 2 WHITCOMB RANDALL W · CIK 0001218867 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,438 Underlying: Common Stock · 21,438 shares Expires 2026-01-27 F3 · price: Received in connection with the Merger in exchange for a stock option to acquire 288,152 shares of Millendo common stock for $0.33 per share. F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vested on January 28, 2017, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document
December 07, 2018 Filed Dec 11, 2018 19:49 UTC	Tempest Therapeutics, Inc. MLND · Entity 7734	GrantCommon Stock	15,784	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-062127 · doc4.xml · nonDerivative · entry 1 WHITCOMB RANDALL W · CIK 0001218867 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,784 F1 · price: Received in exchange for 212,163 shares of Millendo Therapeutics, Inc. ("Millendo") common stock in connection with merger of Millendo Therapeutics, Inc. into the Issuer (the "Merger"). Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.